Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls

Familial Cancer

Volumn 16, Issue 3, 2017, Pages 433-440

  Saya, Sibel ^a   Killick, Emma ^a,b   Thomas, Sarah ^c   Taylor, Natalie ^c   Bancroft, Elizabeth K ^c   Rothwell, Jeanette ^d   Benafif, Sarah ^a   Dias, Alexander ^a   Mikropoulos, Christos ^a,e   Pope, Jenny ^a   Chamberlain, Anthony ^a   Gunapala, Ranga ^c   Izatt, Louise ^f   Side, Lucy ^g   Walker, Lisa ^h   Tomkins, Susan ⁱ   Cook, Jackie ^j   Barwell, Julian ^k   Wiles, Vicki ^l   Limb, Lauren ^m   Eccles, Diana ^b   Leach, Martin O ^a,c   Shanley, Susan ^c,n   Gilbert, Fiona J ^l   Hanson, Helen ^o   Gallagher, David ^p   Rajashanker, Bala ^d   Whitehouse, Richard W ^d   Koh, Dow Mu ^a,c   Sohaib, S Aslam ^c   Evans, D Gareth ^d   Eeles, Rosalind A ^a,c   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^j SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY OF LEICESTER   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^m NORTHWICK PARK HOSPITAL   (United Kingdom)

ⁿ PETER MACCALLUM CANCER CENTRE   (Australia)

^o ST GEORGE S HOSPITAL   (United Kingdom)

^p MATER PRIVATE HOSPITAL   (Ireland)

more..

Author keywords

Controls; Li Fraumeni syndrome; Screening; TP53 mutation carriers; Whole body MRI

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PROTEIN P53; TP53 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ADULT; ANGIOMYOLIPOMA; ARTICLE; ASTROCYTOMA; ASYMPTOMATIC DISEASE; B CELL LEUKEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CHONDROBLASTIC OSTEOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIOID ANGIOMYOLIPOMA; FEMALE; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; HYSTERECTOMY; KIDNEY CARCINOMA; MALE; MELANOMA; MIDDLE AGED; MULTIPLE CANCER; MYXOSARCOMA; NEPHRECTOMY; NEPHROBLASTOMA; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOCYTOMA; OSTEOSARCOMA; OVARY CANCER; OVARY CYST; PERICARDIUM CYST; PILOT STUDY; POPULATION DYNAMICS; PRIMARY TUMOR; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TERATOMA; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERUS MYOMA; UTERUS SARCOMA; WHOLE BODY MRI; YOUNG ADULT; EARLY CANCER DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; INCIDENCE; MASS SCREENING; MUTATION; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; WHOLE BODY IMAGING;

ADULT; EARLY DETECTION OF CANCER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MASS SCREENING; MIDDLE AGED; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UNITED KINGDOM; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 85009455142     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-017-9965-1     Document Type: Article

References (29)

1. Varley JM, McGown G, Thorncroft M et al (1997) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57(15):3245–3252
2. Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21(3):313–320. doi: 10.1002/humu.10185
3. Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238
4. Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71(4):747–752
5. Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256
6. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10(2):83–87
7. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP (1998) Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90(8):606–611
8. Mai PL, Best AF, Peters JA et al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 122(23): 3673–3681. doi: 10.1002/cncr.30248
9. Lalloo F, Varley J, Ellis D, et al. (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet (London, England) 361(9363): 1101–1112 doi: 10.1016/s0140-6736(03)12856-5
10. Villani A, Shore A, Wasserman JD et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. The Lancet Oncol. doi: 10.1016/S1470-2045(16)30249-2
11. Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. The Lancet Oncol 12(6):559–567. doi: 10.1016/S1470-2045(11)70119-X
12. Ballinger ML, Mitchell G, Thomas DM (2015) Surveillance recommendations for patients with germline TP53 mutations. Curr Opin Oncol 27(4):332–337. doi: 10.1097/CCO.0000000000000200
13. McBride KA, Ballinger ML, Killick E et al (2014) Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 11(5):260–271. doi:10.1038/nrclinonc.2014.41
14. Caron O et al. (2011) Evaluation of whole body mri for early detection of cancers in subjects with P53 mutation (Li-Fraumeni Syndrome) (LIFSCREEN). In ASCO Annual Meeting Proceedings 31(15):TPS1607
15. Masciari S, Van den Abbeele AD, Diller LR et al (2008) F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299(11):1315–1319 p[doi]
16. Nogueira STS, Lima ENP, Nóbrega AF et al (2015) (18)F-FDG PET-CT for surveillance of Brazilian patients with Li-Fraumeni Syndrome. Front Oncol 5:38. doi:10.3389/fonc.2015.00038
17. Brito JP., Morris JC, Montori VM (2013) Surveillance study investigating whole body magnetic resonance imaging and other diagnostic procedures in people at high risk of cancer
18. Heymann S, Delaloge S, Rahal A et al (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5:104
19. Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43(4):289–294. doi: 10.1136/jmg.2005.036319
20. StataCorp (2015) Stata Statistical Software: Release 14. StataCorp LP, College Station
21. Bougeard G, Renaux-Petel M, Flaman JM et al (2015) Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol 33(21):2345–2352. doi: 10.1200/JCO.2014.59.5728
22. Evans DG, Kesavan N, Lim Y et al (2014) MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 145(3):663–672. doi: 10.1007/s10549-014-2931-9
23. Evans DG, Lennard F, Pointon LJ et al (2009) Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. Cancer Epidemiol Biomarkers Prev 18(7):2123–2131. doi: 10.1158/1055-9965.EPI-09-0138
24. Hoang HLT, Ensor K, Rosen G, Leon Pachter H, Raccuia JS (2014) Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma. Intl J Surg Oncol 2014:8. doi: 10.1155/2014/919323
25. Schomas DA, Laack NNI, Rao RD, et al. (2009) Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-Oncology 11(4): 437–445 doi: 10.1215/15228517-2008-102
26. Pepper C, Thomas A, Hoy T et al. (2003) Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell cycle (Georgetown, Tex) 2(1): 53–8
27. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI (2010) Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 31(2):143–150. doi: 10.1002/humu.21151
28. Saifudeen Z, Dipp S, El-Dahr SS (2002) A role for p53 in terminal epithelial cell differentiation. J Clin Invest 109(8):1021–1030. doi: 10.1172/JCI13972
29. Saifudeen Z, Dipp S, Stefkova J, Yao X, Lookabaugh S, El-Dahr SS (2009) p53 regulates metanephric development. J Am Soc Nephrol 20(11):2328–2337. doi:10.1681/ASN.2008121224